Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C

Robert J. Fontana, Linas A. Bieliauskas, Carla Back-Madruga, Karen L. Lindsay, Heather J. Litman, Anna S.F. Lok, Ziad Kronfol

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVES: Neuropsychiatric toxicity is a common dose-limiting side effect of interferon therapy. The primary aim of this study was to determine whether patients receiving long-term low-dose peginterferon therapy had a higher incidence of cognitive side effects compared with untreated patients enrolled in the Hepatitis C Antiviral Long-Term treatment against Cirrhosis (HALT-C) Trial. METHODS: A total of 129 patients with chronic hepatitis C and advanced fibrosis completed a battery of 10 neuropsychological tests and the Beck Depression Inventory at pretreatment baseline and at months 12, 24, 36, and 48 while receiving long-term peginterferonα2a (90 μg/week) or no therapy during the randomized phase of the HALT-C Trial. Cognitive impairment was defined as a global deficit score (GDS) ≥1.0. Results: The mean age was 51.2 years, 67% were male, and 42% had cirrhosis. After accounting for baseline GDS scores, the mean GDS scores did not significantly change over time (P0.46) nor with treatment group (P0.49). Cognitive function was also not influenced by medication adherence in the 66 patients receiving maintenance peginterferon (P0.14) after controlling for baseline GDS scores and time. Beck Depression scores did not significantly increase over time (P0.60), nor did they vary by treatment group (P0.74). Although 32% of patients experienced objective worsening of their liver disease during follow-up, the frequency and severity of cognitive impairment did not differ in those with and without disease progression (P0.71). Conclusions: Measures of cognitive function were neither influenced by low-dose peginterferon treatment nor with objective evidence of liver disease progression in patients with advanced chronic hepatitis C prospectively followed up for 3.5 years.

Original languageEnglish
Pages (from-to)1551-1560
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume105
Issue number7
DOIs
Publication statusPublished - Jul 2010
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Cognition
Fibrosis
Therapeutics
Hepatitis C
Antiviral Agents
Disease Progression
Liver Diseases
Depression
Medication Adherence
Neuropsychological Tests
Interferons
Maintenance
Equipment and Supplies
Incidence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. / Fontana, Robert J.; Bieliauskas, Linas A.; Back-Madruga, Carla; Lindsay, Karen L.; Litman, Heather J.; Lok, Anna S.F.; Kronfol, Ziad.

In: American Journal of Gastroenterology, Vol. 105, No. 7, 07.2010, p. 1551-1560.

Research output: Contribution to journalArticle

Fontana, Robert J. ; Bieliauskas, Linas A. ; Back-Madruga, Carla ; Lindsay, Karen L. ; Litman, Heather J. ; Lok, Anna S.F. ; Kronfol, Ziad. / Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. In: American Journal of Gastroenterology. 2010 ; Vol. 105, No. 7. pp. 1551-1560.
@article{1aacd388eb164c09914379633e29173c,
title = "Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C",
abstract = "OBJECTIVES: Neuropsychiatric toxicity is a common dose-limiting side effect of interferon therapy. The primary aim of this study was to determine whether patients receiving long-term low-dose peginterferon therapy had a higher incidence of cognitive side effects compared with untreated patients enrolled in the Hepatitis C Antiviral Long-Term treatment against Cirrhosis (HALT-C) Trial. METHODS: A total of 129 patients with chronic hepatitis C and advanced fibrosis completed a battery of 10 neuropsychological tests and the Beck Depression Inventory at pretreatment baseline and at months 12, 24, 36, and 48 while receiving long-term peginterferonα2a (90 μg/week) or no therapy during the randomized phase of the HALT-C Trial. Cognitive impairment was defined as a global deficit score (GDS) ≥1.0. Results: The mean age was 51.2 years, 67{\%} were male, and 42{\%} had cirrhosis. After accounting for baseline GDS scores, the mean GDS scores did not significantly change over time (P0.46) nor with treatment group (P0.49). Cognitive function was also not influenced by medication adherence in the 66 patients receiving maintenance peginterferon (P0.14) after controlling for baseline GDS scores and time. Beck Depression scores did not significantly increase over time (P0.60), nor did they vary by treatment group (P0.74). Although 32{\%} of patients experienced objective worsening of their liver disease during follow-up, the frequency and severity of cognitive impairment did not differ in those with and without disease progression (P0.71). Conclusions: Measures of cognitive function were neither influenced by low-dose peginterferon treatment nor with objective evidence of liver disease progression in patients with advanced chronic hepatitis C prospectively followed up for 3.5 years.",
author = "Fontana, {Robert J.} and Bieliauskas, {Linas A.} and Carla Back-Madruga and Lindsay, {Karen L.} and Litman, {Heather J.} and Lok, {Anna S.F.} and Ziad Kronfol",
year = "2010",
month = "7",
doi = "10.1038/ajg.2010.3",
language = "English",
volume = "105",
pages = "1551--1560",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C

AU - Fontana, Robert J.

AU - Bieliauskas, Linas A.

AU - Back-Madruga, Carla

AU - Lindsay, Karen L.

AU - Litman, Heather J.

AU - Lok, Anna S.F.

AU - Kronfol, Ziad

PY - 2010/7

Y1 - 2010/7

N2 - OBJECTIVES: Neuropsychiatric toxicity is a common dose-limiting side effect of interferon therapy. The primary aim of this study was to determine whether patients receiving long-term low-dose peginterferon therapy had a higher incidence of cognitive side effects compared with untreated patients enrolled in the Hepatitis C Antiviral Long-Term treatment against Cirrhosis (HALT-C) Trial. METHODS: A total of 129 patients with chronic hepatitis C and advanced fibrosis completed a battery of 10 neuropsychological tests and the Beck Depression Inventory at pretreatment baseline and at months 12, 24, 36, and 48 while receiving long-term peginterferonα2a (90 μg/week) or no therapy during the randomized phase of the HALT-C Trial. Cognitive impairment was defined as a global deficit score (GDS) ≥1.0. Results: The mean age was 51.2 years, 67% were male, and 42% had cirrhosis. After accounting for baseline GDS scores, the mean GDS scores did not significantly change over time (P0.46) nor with treatment group (P0.49). Cognitive function was also not influenced by medication adherence in the 66 patients receiving maintenance peginterferon (P0.14) after controlling for baseline GDS scores and time. Beck Depression scores did not significantly increase over time (P0.60), nor did they vary by treatment group (P0.74). Although 32% of patients experienced objective worsening of their liver disease during follow-up, the frequency and severity of cognitive impairment did not differ in those with and without disease progression (P0.71). Conclusions: Measures of cognitive function were neither influenced by low-dose peginterferon treatment nor with objective evidence of liver disease progression in patients with advanced chronic hepatitis C prospectively followed up for 3.5 years.

AB - OBJECTIVES: Neuropsychiatric toxicity is a common dose-limiting side effect of interferon therapy. The primary aim of this study was to determine whether patients receiving long-term low-dose peginterferon therapy had a higher incidence of cognitive side effects compared with untreated patients enrolled in the Hepatitis C Antiviral Long-Term treatment against Cirrhosis (HALT-C) Trial. METHODS: A total of 129 patients with chronic hepatitis C and advanced fibrosis completed a battery of 10 neuropsychological tests and the Beck Depression Inventory at pretreatment baseline and at months 12, 24, 36, and 48 while receiving long-term peginterferonα2a (90 μg/week) or no therapy during the randomized phase of the HALT-C Trial. Cognitive impairment was defined as a global deficit score (GDS) ≥1.0. Results: The mean age was 51.2 years, 67% were male, and 42% had cirrhosis. After accounting for baseline GDS scores, the mean GDS scores did not significantly change over time (P0.46) nor with treatment group (P0.49). Cognitive function was also not influenced by medication adherence in the 66 patients receiving maintenance peginterferon (P0.14) after controlling for baseline GDS scores and time. Beck Depression scores did not significantly increase over time (P0.60), nor did they vary by treatment group (P0.74). Although 32% of patients experienced objective worsening of their liver disease during follow-up, the frequency and severity of cognitive impairment did not differ in those with and without disease progression (P0.71). Conclusions: Measures of cognitive function were neither influenced by low-dose peginterferon treatment nor with objective evidence of liver disease progression in patients with advanced chronic hepatitis C prospectively followed up for 3.5 years.

UR - http://www.scopus.com/inward/record.url?scp=77954423935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954423935&partnerID=8YFLogxK

U2 - 10.1038/ajg.2010.3

DO - 10.1038/ajg.2010.3

M3 - Article

C2 - 20104219

AN - SCOPUS:77954423935

VL - 105

SP - 1551

EP - 1560

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 7

ER -